Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation.

Jacobs, Maartje S

Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. [electronic resource] - The European journal of health economics : HEPAC : health economics in prevention and care Sep 2018 - 957-965 p. digital

Publication Type: Journal Article

1618-7601

10.1007/s10198-017-0942-2 doi


Atrial Fibrillation--therapy
Cost-Benefit Analysis
Electric Countershock
Factor Xa Inhibitors--economics
Humans
Netherlands
Quality of Life
Quality-Adjusted Life Years
Rivaroxaban--economics
Stroke--prevention & control